Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs.
Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs.
复制标题
DOI：
10.1111/jvim.15084
复制
发表时间：
2018-05
影响因子：
2.6
通讯作者：
Chon E
中科院分区：
文献类型：
--
作者：
Fernández R;Chon E
狗的多发性骨髓瘤（MM）通常用美法兰治疗。据报道，每日给药美法兰耐受性良好，并与良好的结果相关。虽然脉冲给药方案已经取得了成功的疗效，但关于这种给药方案对MM犬的长期结果和安全性数据很少。(1)比较脉冲剂量和日剂量美法兰方案的结果和不良事件档案；(2)报告美法兰治疗MM犬的预后因素。我们假设两种方案的结果和耐受性相似。38只诊断为MM的宠物狗接受了脉冲剂量（n = 17）或日剂量（n = 21）的美法兰治疗。回顾性队列研究，评估接受两种方案的狗的结局和不良事件。评估危险因素与预后的相关性。两种方案耐受性良好，效果相似，总中位生存时间为930天。肾脏疾病和中性粒细胞与淋巴细胞比率（NLR）是阴性预后因素，而高钙血症和溶骨性病变在本研究人群中不是预后因素。阳性结果支持使用任何一种给药方案治疗犬MM，肾脏疾病和NLR是负面预后因素。前瞻性、对照和随机研究证实了这些发现。
Multiple myeloma (MM) in dogs typically is treated with melphalan. A daily melphalan dosing schedule reportedly is well tolerated and associated with favorable outcome. Although anecdotally a pulse dose regimen has resulted in successful responses, little long‐term outcome and safety data is available regarding this dosing regimen for dogs with MM. (1) To compare outcome and adverse event profiles between pulse dose and daily dose melphalan schedules and (2) to report prognostic factors in dogs with MM treated with melphalan. We hypothesized that both protocols would have similar outcomes and tolerability. Thirty‐eight client‐owned dogs diagnosed with MM receiving pulse dose (n = 17) or daily dose (n = 21) melphalan. Retrospective cohort study assessing outcome and adverse events in dogs receiving either protocol. Risk factors were evaluated for their prognostic relevance. Both regimens were well tolerated and similarly effective, with an overall median survival time of 930 days. Renal disease and neutrophil‐to‐lymphocyte ratio (NLR) were negative prognostic factors, whereas hypercalcemia and osteolytic lesions were not prognostic factors in this study population. Positive results support the use of either dosing regimen for the treatment of dogs with MM, and renal disease and NLR were negative prognostic factors. Prospective, controlled, and randomized studies are warranted to confirm these findings.
登录
查看更多内容
影响因子：
--
作者：
Hanbali A;Hassanein M;Rasheed W;Aljurf M;Alsharif F
通讯作者：
Alsharif F
影响因子：
20.3
作者：
Bartel, Twyla B.;Haessler, Jeff;Barlogie, Bart
通讯作者：
Barlogie, Bart
影响因子：
3.5
作者：
Kelkitli, Engin;Atay, Hilmi;Turgut, Mehmet
通讯作者：
Turgut, Mehmet
影响因子：
3.8
作者：
Hashizume, Misato;Higuchi, Yoshinobu;Mihara, Masahiko
通讯作者：
Mihara, Masahiko
影响因子：
1.1
作者：
Emms, SG
通讯作者：
Emms, SG